Performance Status as a Prognostic Factor in Japanese Patients With Myeloperoxidase–Antineutrophil Cytoplasmic Antibody–Positive Microscopic Polyangiitis

Tokio Katakura, Ken‐ei Sada, Masayoshi Harigai, Yuki Nakamura, Shouichi Fujimoto, Yukio Yuzawa, Kunihiro Yamagata, Masaki Kobayashi, Tatsuya Atsumi, Takahiko Sugihara, Naoto Tamura, Yoshihiro Arimura, Hirofumi Makino, Izaya Nakaya
ACR Open Rheumatology · Wiley · 2026-11-10 · DOI: 10.1002/acr2.90172

Abstract

Objective This observational study investigated the impact of performance status (PS) on prognosis following remission induction therapy in patients with myeloperoxidase (MPO)–antineutrophil cytoplasmic antibody–positive microscopic polyangiitis (MPA). Methods Patients with MPO–antineutrophil cytoplasmic antibody–positive MPA (MPO‐MPA) and serum creatinine <5.0 mg/dL who were treated at Iwate Prefectural Central Hospital or enrolled in a Japanese multicenter prospective database were included. Patients were categorized by PS (good [0–1] vs poor [2–4]). Remission induction therapy was categorized as glucocorticoid (GC) monotherapy or combination therapy (GC plus immunosuppressants). The primary endpoint was a composite of death or end‐stage kidney disease (ESKD). Outcomes were compared between the PS groups using Kaplan–Meier analysis and Cox proportional hazards models, with stratification by induction therapy. Results Of 290 patients, 189 had good PS. Combination therapy was administered in 28% of patients (cyclophosphamide, 92%; rituximab, 8%). The poor PS group featured an older patient age and higher Birmingham Vasculitis Activity Score (BVAS). In the cohort‐stratified multivariable Cox model adjusted for age, sex, and BVAS, poor PS was independently associated with a higher risk of death or ESKD (hazard ratio [HR] 2.23, 95% confidence interval [CI] 1.09–4.55). Other risk factors included older age and male sex. In exploratory, hypothesis‐generating stratified analyses, the adjusted HRs for poor PS were 1.35 (95% CI 0.57–3.21) and 4.52 (95% CI 1.25–16.30) in the GC monotherapy and combination therapy groups, respectively. Conclusion Poor PS was independently associated with an increased risk of death or ESKD in patients with MPO‐MPA.

Read at publisher →

Similar articles